Andrei Iagaru
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Andrei Iagaru sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Andrei Iagaru: 13 sponsored US clinical trials, 1 recruiting.
Andrei Iagaru sponsors 13 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Former Smoker, with 1 trials.
Top-decile sponsor footprint
Andrei Iagaru ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
NCT05891769
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
NCT03698370
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
NCT04264208
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
NCT03949517
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
NCT03831711
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
NCT03824535
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
NCT03809078
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
NCT03733210
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
NCT02673151
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
NCT03113617
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
NCT02678351
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT02624518
18F-FSPG PET/CT for Cancer Patients on Therapy
NCT02599194
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 10 |
What is open in the Andrei Iagaru pipeline
1 recruiting of 13 indexed (8% open); 11 completed (85%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Former Smoker (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Andrei Iagaru: open-pipeline peers nationwide
Peers matched on 13 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Andrei Iagaru sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 8% open enrollment (± trial volume)
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
- Fresenius Medical Care North America · 8% recruiting · 13 trials
- LG Chem · 8% recruiting · 13 trials
Related
What to do with this Andrei Iagaru page
13 registered trials is a research-attention snapshot, not an endorsement of Andrei Iagaru or any single study.
- 1 of Andrei Iagaru's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Former Smoker is the condition Andrei Iagaru studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Former Smoker trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Andrei Iagaru pipeline card: 13 registered trials from official public datasets.Report a data error.